BioCentury

7:03 PM GMT, Nov 17, 2017
This article and the information contained in BioCentury's publications and services are solely for your own personal, non-transferable licensed use and cannot be shared with any other individuals. For information about adding subscribers to your account or obtaining article reprints, please contact support@biocentury.com.
Clinical Results

ALK's tree allergy SLIT meets in Phase III for birch pollen allergy

In September, ALK-Abello A/S (CSE:ALK-B) reported data from a Phase III trial in 634 patients ages 12-65 with birch pollen

Read the full 202 word article

This article and the information contained in BioCentury's publications and services are solely for your own personal, non-transferable licensed use and cannot be shared with any other individuals. For information about adding subscribers to your account or obtaining article reprints, please contact support@biocentury.com.